Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614898 · ClinicalTrials.gov registry record
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- 67
- Enrollment target
NCT02614898 is a clinical trial that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 67 participants.
The verdict
NCT02614898 was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- 67 participants
- Enrollment target
Study Summary
This was a prospective, open-label study with no participant randomization. Treatment for aHUS was observational and at the discretion of the treating physician. The purpose of this study was to assess disease manifestations of complement-mediated thrombotic microangiopathy (TMA) and evaluate potential clinical predictors of disease manifestations and progression in participants with aHUS with or without eculizumab treatment in the clinical setting.
Interventions
- OTHER Eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2017-10-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614898
The ClinicalTrials.gov registry entry for NCT02614898 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eculizumab is the first listed.
NCT02614898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614898 about?
NCT02614898 is a clinical study titled "Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment". This was a prospective, open-label study with no participant randomization. Treatment for aHUS was observational and at the discretion of the treating physician. The purpose of this study was to assess disease manifestations of complement-mediated thrombotic microangiopathy (TMA) and evaluate potent...
What is the current status of trial NCT02614898?
This trial is currently terminated. The enrollment target is 67 participants. The study started on 2015-11-04. Estimated completion is 2017-10-05.
What interventions are being tested in trial NCT02614898?
The interventions under investigation include: Eculizumab (OTHER).
Who is sponsoring clinical trial NCT02614898?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.